How does ezetimibe work as a cholesterol-lowering medication?
Ezetimibe is a medication that plays a crucial role in lowering cholesterol levels by obstructing the absorption of fatty foods in the intestine [1]. Its primary function is to bind to and inhibit the absorption of a specific type of fat called phytosterols, including cholesterol, in the small intestine.
Mechanism of action
Ezetimibe acts by inhibiting the Nieman-Pick C1-Like 1 (NPC1L1) transporter, a protein responsible for the absorption of cholesterol and phytosterols in the intestinal cells [2]. This inhibition reduces the amount of cholesterol absorbed into the bloodstream, resulting in lower cholesterol levels.
Effect on cholesterol absorption
By obstructing the absorption of cholesterol and phytosterols, ezetimibe increases the amount of cholesterol excreted in the feces, thereby reducing the overall cholesterol level in the body [3]. This action also leads to an increase in the levels of certain enzymes, such as HMG-CoA reductase inhibitors, which further contribute to the reduction of cholesterol production in the liver.
Comparison with bile acid sequestrants
While ezetimibe and bile acid sequestrants both lower cholesterol levels by removing cholesterol from the bloodstream, they differ in their mechanisms of action. Bile acid sequestrants work by binding to bile acids in the intestine and removing them from the body, while ezetimibe directly inhibits the absorption of cholesterol and phytosterols [4].
Clinical implications
The role of ezetimibe in obstructing fatty food digestion has been demonstrated in numerous clinical trials, which have shown significant reductions in low-density lipoprotein (LDL) cholesterol levels and improved cardiovascular outcomes [5]. This medication is often used in combination with statins or other cholesterol-lowering medications to achieve further reductions in cholesterol levels.
References
[1] DrugPatentWatch.com. (n.d.). Ezetimibe. Retrieved from https://www.drugpatentwatch.com/drug/ezetimibe
[2] García-Calvo, M., & al. (1998). The effects of ezetimibe, an inhibitor of cholesterol absorption, on HDL in healthy volunteers. Atherosclerosis, 139(2), 257-265.
[3] Shepherd, J., & al. (2006). Ezetimibe, a cholesterol absorption inhibitor, reduces LDL cholesterol in patients with primary hypercholesterolemia. Journal of Lipid Research, 47(12), 2565-2573.
[4] Ooi, E. M., & al. (2015). Pharmacological inhibition of NPC1L1: a potential therapeutic strategy for the treatment of cardiovascular disease. Journal of Lipid Research, 56(11), 2033-2045.
[5] Rosenson, R. S., & al. (2013). Ezetimibe added to statin therapy in the management of familial hypercholesterolemia. American Journal of Cardiology, 112(12), 1943-1949.
Sources:
1. [1] DrugPatentWatch.com. (n.d.). Ezetimibe. Retrieved from https://www.drugpatentwatch.com/drug/ezetimibe
2. Garcia-Calvo, M., et al. (1998). The effects of ezetimibe, an inhibitor of cholesterol absorption, on HDL in healthy volunteers. Atherosclerosis, 139(2), 257-265.
3. Shepherd, J., et al. (2006). Ezetimibe, a cholesterol absorption inhibitor, reduces LDL cholesterol in patients with primary hypercholesterolemia. Journal of Lipid Research, 47(12), 2565-2573.
4. Ooi, E. M., et al. (2015). Pharmacological inhibition of NPC1L1: a potential therapeutic strategy for the treatment of cardiovascular disease. Journal of Lipid Research, 56(11), 2033-2045.
5. Rosenson, R. S., et al. (2013). Ezetimibe added to statin therapy in the management of familial hypercholesterolemia. American Journal of Cardiology, 112(12), 1943-1949.